As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.

All

    TOGGLE ALL / NONE

Vitae Pharmaceuticals

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Unum Therapeutics

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Synlogic

Next generation
synthetic biology platform
for novel therapeutics

Spero Therapeutics

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Rodin Therapeutics

Enhancing synaptic integrity
for treatment of
neurologic disorders

Padlock Therapeutics

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Numerate

Small molecule
drug design
using statistical modeling

Nimbus Therapeutics

Breakthrough computer-aided
drug design
for transformative medicines

Navitor Pharmaceuticals

Novel therapeutics
targeting
diseases of aging

Lysosomal Therapeutics, Inc.

Discovering new medicines
for severe
neurodegenerative diseases

JenaValve

Minimally invasive
heart valve
devices

Intellia Therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Infacare

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Harbour Antibodies

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

F-Star Alpha Limited

Bispecific antibodies
to improve the treatment
of serious diseases

Egalet Corporation

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

CoStim Pharmaceuticals

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Bicycle Therapeutics

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

Arteaus Therapeutics

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Annovation Biopharma

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Avila Therapeutics

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Stromedix

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Adnexus Therapeutics

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Actelion

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Alnylam Pharmaceuticals

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

MorphoSys

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Exelixis

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Momenta Pharmaceuticals

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Arrow Therapeutics

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

ArQule

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Crucell

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

deCODE genetics

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Micromet

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Novexel

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

U3 Pharma

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

miRagen Therapeutics

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Replimune

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Surface Oncology

Next-generation antibody therapies
targeting the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

AVROBIO

Cell and gene therapies for
rare diseases and cancer
IPO Jun 2018 (NASDAQ: AVRO)

IFM Therapeutics

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Obsidian Therapeutics

New class of
regulated cell and
gene therapies

Delinia

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Magenta Therapeutics

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Translate Bio

First-in-class
RNA therapies
for severe genetic diseases

Disarm Therapeutics

Preventing axonal degeneration
in patients with
neurological diseases

Gemini Therapeutics

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Cadent Therapeutics

Precision neuroscience to
treat neurological and
neuropsychiatric disease

Kymera Therapeutics

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Kyn Therapeutics

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Generation Bio

Titratable, re-dosable genetic
medicines with drug-like properties
for patients with genetic diseases

Zafgen

Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)

Accent Therapeutics

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Akero Therapeutics

Restoring metabolic balance
to treat NASH and other
serious metabolic diseases

HotSpot Therapeutics

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Akrevia Therapeutics

Highly-potent, targeted, and
combinable immuno-oncology
therapeutics